News

NEW YORK, NY, November 10, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, October 18, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY, October 15, 2021 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share. The dividend will be paid on December 15, 2021, to shareholders of record at the close of business

NEW YORK, NY, September 3, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m.

NEW YORK, NY, August 11, 2021 -  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, July 19, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY, July 16, 2021 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share. The dividend will be paid on September 15, 2021, to shareholders of record at the close of business on

NEW YORK, NY, July 15, 2021 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 2.15% Senior Notes due 2031 (the “Social Bonds”)

NEW YORK, NY, June 7, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June: Goldman Sachs Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Bank of America Napa Biopharma

NEW YORK, NY, and PLANEGG, GERMANY, June 2, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals